Core Viewpoint - Rezolute, Inc. has faced significant stock price decline of over 85% following the failure of its Phase 3 sunRIZE study in congenital hyperinsulinism, leading to an investigation by Block & Leviton for potential securities law violations [2][4]. Group 1: Company Performance - Shares of Rezolute fell over 85% on December 11 after the company announced that its Phase 3 sunRIZE study failed to meet its primary or key secondary endpoints [2]. - The company had previously made optimistic statements about the strength of earlier data and the outlook for the program, which may have misled investors [2]. Group 2: Legal Investigation - Block & Leviton is investigating whether Rezolute, Inc. committed securities law violations and may file an action to recover losses on behalf of affected investors [4]. - Investors who have lost money in their Rezolute investment are encouraged to contact Block & Leviton for potential recovery options [3][5]. Group 3: Whistleblower Information - Individuals with non-public information about Rezolute, Inc. are encouraged to assist in the investigation or file a report with the Securities Exchange Commission under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 4: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions of dollars for defrauded investors and representing many of the nation's top institutional investors [7].

Core Viewpoint - Rezolute, Inc. (NASDAQ: RZLT) experienced a significant decline in share price, falling over 85% after the failure of its Phase 3 sunRIZE study in congenital hyperinsulinism, which did not meet its primary or key secondary endpoints. This has raised concerns about potential securities law violations due to misleading statements made by the company regarding earlier data and program outlook [2][4]. Group 1: Company Performance - The share price of Rezolute, Inc. dropped more than 85% on December 11, 2025, following the announcement of the failed clinical trial results [2]. - The Phase 3 sunRIZE study aimed at treating congenital hyperinsulinism did not achieve its primary or key secondary endpoints, leading to investor losses [2]. Group 2: Legal Investigation - Block & Leviton is investigating Rezolute, Inc. for potential securities law violations and may file an action to recover losses for affected investors [4]. - Investors who purchased common stock in Rezolute, Inc. and experienced a decline in share value may be eligible to participate in the investigation, regardless of whether they sold their shares [3]. Group 3: Investor Support - Block & Leviton encourages investors who have lost money to contact them for assistance in recovering losses [5]. - The firm is recognized as a leading securities class action firm, having recovered billions for defrauded investors through litigation [7].

Core Viewpoint - Rezolute, Inc. experienced a significant decline in share price, falling over 85% after the failure of its Phase 3 sunRIZE study in congenital hyperinsulinism, which did not meet its primary or key secondary endpoints. This has raised concerns about potential securities law violations due to misleading statements made by the company regarding earlier data and program outlook [2]. Group 1: Company Performance - Shares of Rezolute, Inc. fell over 85% on December 11, 2025, following the announcement of the failed Phase 3 study [2]. - The company had previously made optimistic statements about the strength of earlier data, which may have misled investors [2]. Group 2: Legal Investigation - Block & Leviton is investigating Rezolute, Inc. for potential securities law violations and may file an action to recover losses for affected investors [4]. - Investors who have lost money in their Rezolute, Inc. investment are encouraged to contact Block & Leviton for more information on recovery options [1][5]. Group 3: Investor Eligibility - Any individual who purchased common stock of Rezolute, Inc. and has seen a decline in their shares may be eligible for recovery, regardless of whether they have sold their investment [3]. Group 4: Whistleblower Information - Individuals with non-public information about Rezolute, Inc. are encouraged to assist in the investigation or file a report with the SEC under the whistleblower program, which offers rewards of up to 30% of any successful recovery [6]. Group 5: Firm Reputation - Block & Leviton is recognized as a leading securities class action firm, having recovered billions for defrauded investors and representing many top institutional investors [7].